Head-To-Head Analysis: Vertex Pharmaceuticals (NASDAQ:VRTX) & C4 Therapeutics (NASDAQ:CCCC)

C4 Therapeutics (NASDAQ:CCCC – Get Free Report) and Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Earnings & Valuation

This table compares C4 Therapeutics and Vertex Pharmaceuticals”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
C4 Therapeutics $35.95 million 8.93 -$104.99 million ($0.72) -3.40
Vertex Pharmaceuticals $12.00 billion 11.11 $3.95 billion $15.54 33.83

Vertex Pharmaceuticals has higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for C4 Therapeutics and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
C4 Therapeutics 1 1 5 0 2.57
Vertex Pharmaceuticals 0 2 25 1 2.96

C4 Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 247.65%. Vertex Pharmaceuticals has a consensus price target of $596.44, suggesting a potential upside of 13.44%. Given C4 Therapeutics’ higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than Vertex Pharmaceuticals.

Profitability

This table compares C4 Therapeutics and Vertex Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
C4 Therapeutics -282.22% -37.71% -26.42%
Vertex Pharmaceuticals 30.70% 21.98% 15.50%

Insider and Institutional Ownership

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

C4 Therapeutics has a beta of 3.16, suggesting that its share price is 216% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats C4 Therapeutics on 12 of the 15 factors compared between the two stocks.

About C4 Therapeutics

(Get Free Report)

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. Founded in 2015, it develops medicines designed to selectively remove disease-causing proteins, with a focus on cancer. The company uses its TORPEDO platform to design targeted protein degraders. These molecules are intended to bind a target protein and recruit the cell’s natural protein-disposal machinery, leading to the protein’s breakdown. C4 Therapeutics’ research and development programs include oral small-molecule candidates for oncology.

About Vertex Pharmaceuticals

(Get Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.